Institut National De La Sante Et De La Recherche Medicale

UniversitÉ Paris Descartes

Universite Dé Lorraine

Assistance Publique - Hopitaux De Paris (aphp)

Aphp (Assistance Publique-Hôpitaux De Paris)

Université Pierre Et Marie Curie - Upmc

Inotrem

Assistance Publique-hopitaux De Paris

Sorbonne Université

Universite Paris Cité

Aphp

Inserm

Nicolas Danchin

Alain Tedgui

Ziad Mallat

Sebastien Gibot

Marc Derive

Hafid Ait-Oufella

Amir Boufenzer

Tabasomme Simon

Tabassome Simon

Sébastien Gibot

A cardiovascular event or disease is prevented or treated in a subject by measuring the expression level of soluble Triggering Receptors Expressed on Myeloid cells-1 (sTREM-1) level in a sample from the subject and comparing it to a reference level. Based on this comparison, subjects that are at risk of having or developing a cardiovascular event or disease are identified, and administered a suitable therapy.

Methods and kits for predicting the risk of having a cardiovascular disease or event

The present invention relates to a method for predicting the survival time of a patient suffering from myocardial infarction or the recurrence of a myocardial infarction. The method comprises the steps of i) determining the expression level of BAFF in a sample from the patient, ii) comparing the expression level with a predetermined reference value and iii) providing a good prognosis of the survival time or a low risk of the recurrence of a myocardial infarction when the expression level is lower than the predetermined reference value and a poor prognosis of the survival time or a high risk of the recurrence of a myocardial infarction when the expression level is higher than the predetermined reference value.

Method of predicting survival time in myocardial infarction patients by measuring BAFF levels

Growing community of inventors

Paris, France

Nicolas Danchin